Blueprint Medicines Corp
BPMC129.460USD
0.000
收盤 10/10, 16:00（美東）報價延遲15分鐘
8.36B總市值
虧損本益比TTM
關於 Blueprint Medicines Corp 公司
Blueprint Medicines Corporation 是一家全球精準治療公司，正在過敏/炎症和腫瘤/血液學兩個領域發明改變生命的藥物。該公司向美國和歐洲的患者提供其獲批的藥物，包括 AYVAKIT/AYVAKYT (avapritinib) 和 GAVRETO (pralsetinib)，並在全球範圍內推進針對系統性肥大細胞增多症 (SM)、肺癌、乳腺癌和其他基因組定義的癌症以及癌症免疫療法的多個項目。該公司的產品線還包括 Elenestinib (BLU-263) (KIT)、AYVAKIT (avapritinib) (KIT)、野生型 KIT 研究項目、GAVRETO (pralsetinib) (RET)、BLU-945 (EGFR)、BLU-525 (EGFR)、BLU-451 (EGFR 外顯子 20 插入)、BLU-222 (CDK2)、AYVAKIT (PDGFRA)、GAVRETO (RET)、BLU-222 (CDK2) 和 BLU-852 (MAP4K1)。該公司正在開發一種口服、有效且高選擇性的試驗性 KIT 抑制劑 Elenestinib (BLU-263)，用於治療惰性 SM 和其他肥大細胞疾病。
Blueprint Medicines Corp簡介
公司代碼BPMC
公司名稱Blueprint Medicines Corp
上市日期Apr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
員工數量649
證券類型Ordinary Share
年結日Apr 30
公司地址45 Sidney Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02139
電話16173747580
網址https://www.blueprintmedicines.com/
公司代碼BPMC
上市日期Apr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
Blueprint Medicines Corp公司高管
名稱
名稱/職務
職務
持股
持股變動
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+22.22%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-68.90%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
Mr. Michael J. Tolpa
Mr. Michael J. Tolpa
Director
Director
--
--
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
--
--
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
--
-100.00%
Ms. Jenna Cohen
Ms. Jenna Cohen
Vice President and Head, Investor Relations
Vice President and Head, Investor Relations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+22.22%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-68.90%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
收入明細
單位: USD更新時間: 4月6日 週日
單位: USD更新時間: 4月6日 週日
FY2024Q3
FY2024Q2
FY2024Q1
業務USD
名稱
營收
佔比
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
地區USD
名稱
營收
佔比
United States
113.13M
88.26%
Rest of the world
15.05M
11.74%
業務
地區
業務USD
名稱
營收
佔比
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
股東統計
更新時間: 8月13日 週三
更新時間: 8月13日 週三
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.90%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.29%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
其他
63.83%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.90%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.29%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
其他
63.83%
股東類型
持股股東
佔比
Investment Advisor
42.13%
Hedge Fund
26.61%
Investment Advisor/Hedge Fund
24.80%
Research Firm
3.16%
Sovereign Wealth Fund
1.66%
Individual Investor
0.93%
Bank and Trust
0.78%
Pension Fund
0.78%
Venture Capital
0.41%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
701
68.81M
106.41%
-3.22M
2025Q1
702
71.75M
110.98%
-1.27M
2024Q4
657
69.17M
108.25%
-2.83M
2024Q3
644
67.12M
105.97%
-7.85M
2024Q2
622
68.23M
108.95%
-6.94M
2024Q1
615
67.81M
110.73%
-5.62M
2023Q4
612
65.87M
108.35%
-10.02M
2023Q3
602
66.47M
109.56%
-7.64M
2023Q2
614
65.78M
108.78%
-8.60M
2023Q1
625
65.63M
109.42%
-10.28M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
--
0%
-223.92K
-100.00%
T. Rowe Price Associates, Inc.
--
0%
-3.95M
-100.00%
BlackRock Institutional Trust Company, N.A.
--
0%
-182.70K
-100.00%
State Street Global Advisors (US)
--
0%
-453.14K
-100.00%
Geode Capital Management, L.L.C.
--
0%
+18.37K
-100.00%
Macquarie Investment Management
--
0%
-364.73K
-100.00%
AllianceBernstein L.P.
--
0%
-430.85K
-100.00%
查看更多
持股ETF
更新時間: 8月6日 週三
更新時間: 8月6日 週三
機構名稱
佔比
ProShares Merger ETF
3.21%
AltShares Event-Driven ETF
1.43%
ProShares Ultra Nasdaq Biotechnology
0.92%
Goldman Sachs Future Health Care Equity ETF
0.84%
Hypatia Women CEO ETF
0.73%
First Trust Mid Cap Growth AlphaDEX Fund
0.58%
iShares Russell 2000 Growth ETF
0.54%
WisdomTree BioRevolution Fund
0.49%
SoFi Next 500 ETF
0.45%
JPMorgan Fundamental Data Science Small Core ETF
0.43%
查看更多
ProShares Merger ETF
佔比3.21%
AltShares Event-Driven ETF
佔比1.43%
ProShares Ultra Nasdaq Biotechnology
佔比0.92%
Goldman Sachs Future Health Care Equity ETF
佔比0.84%
Hypatia Women CEO ETF
佔比0.73%
First Trust Mid Cap Growth AlphaDEX Fund
佔比0.58%
iShares Russell 2000 Growth ETF
佔比0.54%
WisdomTree BioRevolution Fund
佔比0.49%
SoFi Next 500 ETF
佔比0.45%
JPMorgan Fundamental Data Science Small Core ETF
佔比0.43%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
